Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lutathera under the microscope: how does it perform in real patients?

NCT ID NCT04727723

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 164 adults with advanced, progressive neuroendocrine tumors of the gut or pancreas who were treated with Lutathera (a radioactive drug) in normal hospital settings. Researchers measured how long patients lived without their cancer getting worse and how many tumors shrank. The goal is to see if Lutathera works as well in everyday practice as it did in earlier clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lutathera (177Lu-oxodotreotide)
What this could lead to
If results are positive, this could confirm that Lutathera works well in everyday clinical practice for controlling advanced GEP-NETs, potentially improving treatment guidelines.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. The study is also completed, meaning findings are already known and may not lead to new breakthroughs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR

Contacts and locations

Locations

  • Novartis Investigative Site

    Alessandria, Italy

  • Novartis Investigative Site

    Bologna, Italy

  • Novartis Investigative Site

    Brescia, Italy

  • Novartis Investigative Site

    Cona, Italy

  • Novartis Investigative Site

    Florence, Italy

  • Novartis Investigative Site

    Latina, Italy

  • Novartis Investigative Site

    Meldola, Italy

  • Novartis Investigative Site

    Messina, Italy

  • Novartis Investigative Site

    Milan, Italy

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Negrar, Italy

  • Novartis Investigative Site

    Padova, Italy

  • Novartis Investigative Site

    Pisa, Italy

  • Novartis Investigative Site

    Reggio Emilia, Italy

  • Novartis Investigative Site

    Rionero in Volture, Italy

  • Novartis Investigative Site

    Roma, Italy

  • Novartis Investigative Site

    Rozzano, Italy

  • Novartis Investigative Site

    Torino, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.